<DOC>
	<DOCNO>NCT01117012</DOCNO>
	<brief_summary>The primary objective study evaluate safety long-term VX-770 treatment participant cystic fibrosis ( CF ) . The secondary objective study evaluate efficacy long-term VX-770 treatment subject CF .</brief_summary>
	<brief_title>Rollover Study VX-770 Cystic Fibrosis Subjects</brief_title>
	<detailed_description>This open-label , rollover study orally administer VX-770 conducted participant CF evaluate safety efficacy long-term VX-770 treatment . Participants previously enrol Study 102 ( VX08-770-102/NCT00909532 ) Study 103 ( VX08-770-103/NCT00909727 ) , meet certain criterion eligible enroll study ( Study 105/VX08-770-105/NCT01117012 ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1 . Participants complete assigned study treatment Study 102 Study 103 2 . Participants females childbearing potential must negative urine pregnancy test Day 1 ( first dose VX770 ) 3 . Participants able understand comply protocol requirement , restriction , instruction likely complete study plan , judge investigator 4 . Participants child bear potential sexually active must meet contraception requirement 5 . Participants must sign informed consent form ( ICF ) , appropriate , assent must obtain 1 . Participants history illness condition , opinion investigator , might confound result study pose additional risk administer study drug subject 2 . Participants history study treatment intolerance observe previous VX770 study , opinion investigator , might pose additional risk administer study drug subject 3 . Participants pregnant , planning pregnancy , breastfeeding , willing follow contraception requirement 4 . Participants take inhibitor inducer Cytochrome P450 3A4 ( CYP3A4 ) , include certain herbal medication ( example , St. John 's Wort ) grapefruit/grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>